Study links Wegovy to increased hair loss risk
(NewsNation) — A new study from the University of British Columbia says an ingredient used in popular weight-loss drugs could have side effects linked to hair loss.
Semaglutide, the main ingredient in Ozempic and Wegovy, has been linked to an increased likelihood of hair loss.
Researchers assessed data from 16 million patients from 2006 to 2020 and compared the effects of users taking semaglutide-based drugs to those taking Contrave, a bupropion/naltrexone drug.
'Those considering using semaglutide strictly for weight loss might want to factor in hair loss as apossible limitation of these drugs, and in particular, women who may want to use semaglutide,' the study said.
TikTok removes controversial filter that made users look overweight
The study authors noted that more research is required to further analyze the relationship between hair loss and 'GLP-1 agonists.'
'The risk-benefit calculus to treatment initiation may be different for those with diabetes or morbidobesity and they may be more willing to accept hair loss as a potential risk of semaglutidetreatment than those using semaglutide for recreational weight loss.'
Novo Nordisk, the company manufacturing both drugs, told CNBC it 'remains confident in the benefit-risk profile of our GLP-1 medicines, when used consistent with their indications and product labeling.'
The company has conducted studies showing that there are risks of hair loss when taking Wegovy.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Chartbreaker: Mariah the Scientist on Her Biggest Hit's ‘Casual' Start & Using Her Platform to ‘Help People Feel Included'
True to her name, Mariah the Scientist's songs are often the result of several months, and sometimes years, spent combining different elements of choruses and verses until finding the right mixture. But when it came time for the 27-year-old to unveil her latest single, the sultry 'Burning Blue,' the R&B singer-songwriter was at a crossroads. So, she experimented with her promotional strategy, too — and achieved the desired momentum. 'Mariah felt she was in a space between treating [music] like a hobby and this being her career,' recalls Morgan Buckles, the artist's sister and manager. And so, they crafted a curated, monthlong rollout — filled with snippets, TikTok posts encouraging fan interaction and various live performances — that helped the song go viral even before its early May arrival. Upon its release, Mariah the Scientist scored her first solo Billboard Hot 100 entry and breakthrough hit. More from Billboard Young Thug Recalls Getting 'Stood Up' By Mariah The Scientist on Their First Date Chappell Roan Did the Viral 'Apple' Dance During Charli xcx's Primavera Sound Set: 'Love You B-ch!' 50 Years Ago, Elton John Became First Artist to Enter Billboard 200 at No. 1 - Just How 'Fantastic' Was the Feat? Mariah Amani Buckles grew up in Atlanta, singing from an early age. She attended St. John's University in New York and studied biology, but ultimately dropped out to pursue music. Her self-released debut EP, To Die For, arrived in 2018, after which she signed to RCA Records and Tory Lanez's One Umbrella label. She stayed in those deals until 2022 — releasing albums Master and Ry Ry World in 2019 and 2021, respectively — before leaving to continue as an independent artist. 'Over time, you start realizing [people] want you to change things,' Mariah says of her start in the industry. 'Everybody wants to control your art. I don't want to argue with you about what I want, because if we don't want the same things, I'll just go find somebody who does.' In 2023, after six months as an independent artist, Mariah signed a joint venture deal with Epic Records and released her third album, To Be Eaten Alive, which became her first to reach the Billboard 200. She then made two Hot 100 appearances as a featured artist in early 2024, on 'IDGAF' with Tee Grizzley and Chris Brown and 'Dark Days' with 21 Savage. 'Burning Blue' marks Mariah's first release of 2025 — and first new music since boyfriend Young Thug's release from jail following his bombshell YSL RICO trial. The song takes inspiration from Purple Rain-era Prince balladry with booming drums and warbling bass — and Mariah admits that the Jetski Purp-produced beat on YouTube (originally titled 'Blue Flame') likely influenced some lyrics, too. She initially recorded part of the track over an unofficial MP3 rip, but after Purp caught wind of it and learned his girlfriend was a fan, he gave Mariah the beat. Mariah then looped in Nineteen85 (Drake, Nicki Minaj, Khalid) to flesh out the production. 'I [recorded the first part of 'Burning Blue'] in the first room I recorded in when I first started making music in Atlanta,' Mariah says. 'I don't want to say it was a throwaway, but it was casual. I wrote some of it, and then I put it to the side.' Once Epic A&R executive Jennifer Raymond heard the in-progress track, she insisted on its completion enough that Mariah and her collaborators convened in Cabo San Lucas, Mexico, in February to finish the song. By that point, they sensed something special. Mariah shared a low-quality snippet on Instagram, but Morgan — who joined as a tour manager in 2022 — knew a more polished presentation was needed to reach its full potential. Morgan eyed Billboard's Women in Music event in late March as the launchpad for the 'Burning Blue' campaign. Though Mariah wasn't performing or presenting at the event, Morgan wanted to take advantage of her already being in glam to shoot a flashier teaser than Mariah's initial IG story, which didn't even show her face. The two decided on a behind-the-scenes, pre-red carpet clip soundtracked by a studio-quality snippet of 'Burning Blue.' Posted on April 1, that clip showcased its downtempo chorus and Mariah's silky vocal and has since amassed more than two million views, with designer Jean Paul Gaultier's official TikTok account sharing the video to its feed. Ten days later, Morgan advised Mariah to share another TikTok, this time with an explicit call to action encouraging fans to use the song in their own posts and teasing that she 'might have a surprise' for fans with enough interaction. Mariah then debuted the song live on April 19 during a set at Howard University — a smart exclusive for her core audience — as anticipation for the song continued to build. Two weeks later, 'Burning Blue' hit digital service providers on May 2, further fueled by a Claire Bishara-helmed video on May 8 that has over 7 million YouTube views. 'We're at the point where opportunity meets preparation,' Morgan reflects of the concerted but not overbearing promotional approach. '[To Be Eaten Alive] happened so fast, I didn't even know what 'working' a project meant. This time, I studied other artists' rollouts to figure out how to make this campaign personal to her.' 'Burning Blue' debuted at No. 25 on the Billboard Hot 100 dated May 17, marking Mariah's first time in the top 40. Following its TikTok-fueled debut, the song has shown legs at radio too, entering Rhythmic Airplay, R&B/Hip-Hop Airplay and Mainstream R&B/Hip-Hop Airplay — to which Morgan credits Epic's radio team, spearheaded by Traci Adams and Dontay Thompson. '[The song] ended up going to radio a week earlier [than scheduled] because Dontay was like, 'If y'all like this song so much, then play it!,' and they did,' Morgan jokes. With 'Burning Blue' proving to be a robust start to an exciting new chapter, Mariah has a bona fide hit to start the summer as she prepares to unleash her new project, due before the fall. She recently performed the track on Jimmy Kimmel Live! and will have the opportunity to fan the song's flames in front of festival audiences including Governors Ball in June and Lollapalooza in August. But as her following continues to heat up, Mariah's mindset is as cool as ever. 'I'll take what I can get,' Mariah says. 'As long as I can use my platform to help people feel included or understood, I'm good.' A version of this story appears in the June 7, 2025, issue of Billboard. Best of Billboard Chart Rewind: In 1989, New Kids on the Block Were 'Hangin' Tough' at No. 1 Janet Jackson's Biggest Billboard Hot 100 Hits H.E.R. & Chris Brown 'Come Through' to No. 1 on Adult R&B Airplay Chart
The Hill
4 hours ago
- The Hill
Beyond MAHA: Defeating obesity requires a new strategy
Obesity is a major health problem facing our country. According to the CDC, more than 40 percent of the U.S. population is obese, defined as having a body-mass index above 30. As astounding at that number is, it is perhaps even more surprising that nearly 20 percent of children in the U.S. are obese. Obesity leads to significant health challenges, including diabetes, stroke, cardiovascular disease and liver disease. It is clear that as a nation we must face this crisis on multiple fronts. Diet and exercise certainly help, and it's critical to ensure that people of all socioeconomic backgrounds have access to healthy foods (free of preservatives, unnecessary dyes, high fructose corn syrups etc.) and are educated in making healthy lifestyle choices. The MAHA or 'Make America Healthy Again' movement has highlighted this as one of its key objectives, and if it is successful, we should see an impact on obesity — especially in children, where diet and exercise have a huge impact on weight-related health outcomes. Obesity in adults, however, is often more challenging. Many adults with obesity struggle to lose weight, despite considerable efforts to modify their lifestyle through diet and exercise. This is because our metabolism changes as we age, and many adults who are overweight develop metabolic dysfunction or 'metabolic syndrome,' which then further perpetuates weight gain and exacerbates the situation. It has become clear in recent years that many people struggling with obesity require medical intervention – not just lifestyle intervention – and that prescriptions can substantially improve weight loss. The explosion in use of GLP-1 agonists, such as Wegovy and Zepbound, over the last two years has underscored the need for medical intervention in obese and overweight patients. Currently, about 6 percent of the U.S. population, or 15 million people, are on GLP-1 weight loss treatments, and the numbers are only expected to increase. However, while most patients lose 10 percent to 25 percent of their body weight while on a GLP-1, they do not maintain GLP-1 treatment in the long-term, with approximately 80 percent of patients discontinuing treatment within 1 year. Gastrointestinal side effects, injectable administration, and high cost have prevented long-term use of GLP-1's for weight maintenance. And unfortunately, most patients gain back all the weight after stopping the medication. Healthcare professionals and the pharmaceutical industry now recognize that obesity — like most other medical conditions — requires an 'arsenal' of treatments, rather than a one-size-fits-all approach. Post-GLP-1 weight maintenance is now widely recognized as an emerging unmet need. And patients who are not candidates for or cannot tolerate GLP-1s require alternatives. Diet and lifestyle modifications are important alongside prescription medications in fighting obesity. If we are going to be successful in overcoming this major health crisis, we need to ensure that both the pharmaceutical industry and groups like MAHA work hand in hand. Both treatment and prevention are critical in order to regain control of our nation's health. Dr. Shoshana Shendelman, Ph.D. is a scientist and entrepreneur who has founded numerous biotech companies. She is a pioneer in the development of drugs and therapeutics for rare and underserved diseases. Currently she is Vice Chair of the Advisory Board of Columbia University Medical Center and Columbia University Vagelos College of Physicians and Surgeons.
Gizmodo
4 hours ago
- Gizmodo
The Ugly Side of Weight-Loss Drugs: Rotten Breath, Damaged Teeth, and Dry Mouth
Ozempic and Wegovy have been hailed as wonder drugs when it comes to weight loss. But as the drug has become more widely used, a number of unintended side-effects have become apparent—with the weight loss drug affecting the appearance of everything from your butt to your feet. 'Ozempic face' is another commonly reported consequences of using these popular weight loss drugs. This is a sunken or hollowed out appearance the face can take on in people taking weight loss drugs. It can also increase signs of ageing—including lines, wrinkles and sagging skin. This happens because semaglutide (the active ingredient in both Ozempic and Wegovy) isn't localised to act just on the fat we want to lose. Instead, it targets all of our body's fat—including in the face. But it isn't just the appearance of your face that semaglutide affects. These drugs may also affect the mouth and teeth, too. And these side-effects could potentially lead to lasting damage. Dry mouth Semaglutide effects the salivary glands in the mouth. It does this by reducing saliva production (hyposalivation), which can in turn lead to dry mouth (xerostomia). This means there isn't enough saliva to keep the mouth wet. It isn't exactly clear why semaglutide has this effect on the salivary glands. But in animal studies of the drug, it appears the drug makes saliva stickier. This means there's less fluid to moisten the mouth, causing it to dry out. GLP-1 receptor agonist drugs (such as semaglutide) can also reduce water intake by affecting areas in the brain responsible for thirst. Low fluid intake further reduces saliva production, and may even cause the saliva to become thick and frothy and the tongue to become sticky. Bad breath One other commonly reported unwanted effect by semaglutide users is bad breath (halitosis). When there's less saliva flowing through the mouth, this encourages bacteria that contribute to bad breath and the formation of cavities to thrive. These bacterial species include Streptococcus mutans and some strains of Lactobacillus. Another species that has been shown to thrive in conditions where saliva is reduced is Porphyromonas gingivalis. This bacteria is a significant contributor to the production of volatile sulphur compounds, which cause the foul odours characteristic of halitosis. Another factor that might explain why semaglutide causes bad breath is because less saliva being produced means the tongue isn't cleaned. This is the same reason why your 'morning breath' is so bad, because we naturally produce less saliva at night. This allows bacteria to grow and produce odours. Case report images show some people taking semaglutide have a 'furry'-like or coated appearance to their tongue. This indicates a build up of bacteria that contribute to bad breath. Tooth damage One of the major side-effects of Ozempic is vomiting. Semaglutide slows how quickly the stomach empties, delaying digestion which can lead to bloating, nausea, and vomiting. Repeated vomiting can damage the teeth. This is because stomach acid, composed primarily of hydrochloric acid, erodes the enamel of the teeth. Where vomiting occurs over a prolonged period of months and years the more damage will occur. The back surface of the teeth (palatal surface) closest to the tongue are more likely to see damage–and this damage may not be obvious to the sufferer. Vomiting also reduces the amount of fluid in the body. When combined with reduced saliva production, this puts the teeth at even greater risk of damage. This is because saliva helps neutralise the acid that causes dental damage. Saliva also contributes to the dental pellicle—a thin, protective layer that the saliva forms on the surface of the teeth. It's thickest on the tongue-facing surface of the bottom row of teeth. In people who produce less saliva, the dental pellicle contains fewer mucins—a type of mucus which helps saliva stick to the teeth. Reducing the risk of damage If you're taking semaglutide, there are many things you can do to keep your mouth healthy. Drinking water regularly during the day can help to keep the oral surfaces from drying out. This helps maintain your natural oral microbiome, which can reduce the risk of an overgrowth of the bacteria that cause bad breath and tooth damage. Drinking plenty of water also enables the body to produce the saliva needed to prevent dry mouth, ideally the recommended daily amount of six to eight glasses. Chewing sugar-free gum is also a sensible option as it helps to encourage saliva production. Swallowing this saliva keeps the valuable fluid within the body. Gums containing eucalyptus may help to prevent halitosis, too. There's some evidence that probiotics may help to alleviate bad breath, at least in the short term. Using a probiotic supplements or consuming probiotic-rich foods (such as yoghurt or kefir) may be a good idea. Practising good basic oral hygiene, tooth brushing, reducing acidic foods and sugary drinks and using a mouthwash all help to protect your teeth as well. Women are twice as likely to have side-effects when taking GLP-1 receptor agonists–including gastrointestinal symptoms such as vomiting. This may be due to the sex hormones oestrogen and progesterone, which can alter the gut's sensitivity. To avoid vomiting, try eating smaller meals since the stomach stays fuller for longer while taking semaglutide. If you are sick, don't immediately brush your teeth as this will spread the stomach's acid over the surface of the teeth and increase the risk of damage. Instead, rinse your mouth out with water or mouthwash to reduce the strength of the acid and wait at least 30 minutes before brushing. It isn't clear how long these side effects last, they'll likely disappear when the medication is stopped, but any damage to the teeth is permanent. Gastrointestinal side-effects can last a few weeks but usually resolve on their own unless a higher dose is taken. Adam Taylor, Professor of Anatomy, Lancaster University. This article is republished from The Conversation under a Creative Commons license. Read the original article.
